Safety and Immunogenicity of an AS03B-Adjuvanted Inactivated Tetravalent Dengue Virus Vaccine Administered on Varying Schedules to Healthy U.S. Adults: A Phase 1/2 Randomized Study-Reference-Cited by-同舟云学术

Safety and Immunogenicity of an AS03B-Adjuvanted Inactivated Tetravalent Dengue Virus Vaccine Administered on Varying Schedules to Healthy U.S. Adults: A Phase 1/2 Randomized Study

Published:2020-07-08 Issue:1 Volume:103 Page:132-141
ISSN:0002-9637
Container-title:The American Journal of Tropical Medicine and Hygiene
language:en
Short-container-title:

Author:

Lin Leyi¹,Lyke Kirsten E.²,Koren Michael¹,Jarman Richard G.¹,Eckels Kenneth H.¹,Lepine Edith³,McArthur Monica A.²,Currier Jeffrey R.¹,Friberg Heather¹,Moris Philippe⁴,Keiser Paul B.¹,De La Barrera Rafael¹,Vaughn David W.³,Paris Robert M.³,Thomas Stephen J.¹,Schmidt Alexander C.³

Affiliation:

1. Walter Reed Army Institute of Research, Silver Spring, Maryland;

2. Center for Vaccine Development and Global Health (CVD), University of Maryland, Baltimore, Maryland;

3. GSK, Rockville, Maryland;

4. GSK, Rixensart, Belgium

Publisher

American Society of Tropical Medicine and Hygiene

Subject

Virology,Infectious Diseases,Parasitology

Reference22 articles.

1. Dengue vaccine: WHO position paper–September 2018;Wkly Epidemiol Rec,2018

2. The global burden of dengue: an analysis from the Global Burden of Disease Study 2013;Stanaway;Lancet Infect Dis,2016